Month: November 2022

Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020 was written by Green, Francis G.;Park, Kyunghun;Burckart, Gilbert J.. And the article was included in Journal of Clinical Pharmacology in 2021.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Dosing is a critical aspect of drug development in pediatrics that has led to trial failures and the inability to label the drug for pediatric use by the US Food and Drug Administration. Developing a structured approach for pediatric dose selection requires knowledge of the current approaches and their success or failure. This study describes the current experience with pediatric dosing methods from 2012 to 2020 and had 2 primary objectives: (1) to identify how the initial pediatric dose was selected and (2) to identify the pivotal dosing strategy used to identify the initially selected dose for safety and efficacy for pediatric clin. trials. Through Sept. 2020, a total of 275 pediatric drug development programs were characterized for initial and pivotal dosing strategies. The success rate for labeling for pediatric use was 76.4%. The most common initial dosing strategy was previous experience with the product, followed by allometric scaling and exposure matching with adults. The most common pivotal dosing strategy was titration to target response in 33% of programs, with the second and third most common being pharmacokinetic/pharmacodynamic studies (30%) and exposure matching (20%), resp. Addnl., about one-half of pediatric programs incorporated model-informed drug development. The emergence of titration to target response may signal a shift toward precision medicine in pediatric patients. Future work in pediatric drug dose selection should move toward the development of a structured pediatric dose selection approach. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A new approach to vocal cord leukoplakia and evaluation of proton pump ınhibitor treatment. was written by Sezen Goktas, Seda;Dogan, Remzi;Yenigun, Alper;Calim, Omer Faruk;Ozturan, Orhan;Tugrul, Selahattin. And the article was included in European archives of oto-rhino-laryngology in 2019.Electric Literature of C18H20N3NaO3S The following contents are mentioned in the article:

PURPOSE: Our aim is identify a new approach to vocal cord leukoplakia treatment and detect to efficiency of proton pump inhibitors. STUDY DESIGN: Prospective, nonrandomized experimental clinical trial. METHODS: A ‘First Assessment Scale’ was prepared. This scale included the lesion’s and the patient’s characteristics. Using this scale, 24 patients included to the study. 20 mg rabeprazole twice daily was applied to all patients. At the end of 3rd month, a ‘Second Assessment Scale’ was used and two groups created. In group 1, 19 patients were accepted to responsive for the therapy and received the same therapy. The group 2 was included five patients that accepted unresponsive to treatment and directed to surgery. All patients received the same treatment additionally 3 months. At the end of 6th month, the Reflux Symptom Index (RSI), the Reflux Finding Score (RFS) and the Red-Green-Blue (RGB) values evaluated and comparisons were made. RESULTS: The RSI and RFS values were significantly decreased in all patients. The Red values were significantly decreased with treatment in group 1, but the Green and Blue values were not. In group 2, the RGB values were not showed the significant differences. In conclusion, seven patients (29,2%) showed complete lesion regression, 12 patients (50%) showed partial lesion regression and five patients (20,8%) showed no response to treatment. CONCLUSIONS: The proton pump inhibitor treatment may be beneficial for the selected patients. The scales that we prepared were useful for lesion assesment. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Electric Literature of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Electric Literature of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

[Dual therapy with rabeprazole and amoxicillin four times daily for 14 days for the first-line eradication of Helicobacter pylori infection]. was written by Suo, B J;Tian, X L;Li, C L;Song, Z Q. And the article was included in Zhonghua yi xue za zhi in 2019.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Objective: To investigate the efficacy, safety and compliance of dual therapy for the first-line eradication of Helicobacter pylori infection through a prospective, single-center and open-label cohort study. Methods: From March 2014 to September 2018, 200 naïve patients with Helicobacter pylori infection and dyspepsia received 14-day dual therapy (rabeprazole 10mg and amoxicillin 500 mg, four times daily orally). Safety and compliance were assessed 1-3 days after eradication. The therapeutic outcome was determined by (13)C-urea breath test 4-8 weeks after eradication. Some patients underwent strain culture, antibiotic sensitivity testing and CYP2C19 polymorphism assay. Results: The eradication rates of dual therapy: intention-to-treat analysis 87.5% (95% confidence interval 82.5%-91.5%), modified intention-to-treat analysis 90.2% (86.1%-94.3%) and per-protocol analysis 91.0% (86.3%-94.7). 21.2% of patients had adverse reactions, the majority were mild to moderate, and only 1.5% of patients discontinued medication because of intolerance to adverse reactions. Patients with good compliance accounted for 96.0%. Variate analyses showed that poor compliance and amoxicillin resistance were the independent risk factors for eradication failure. Conclusions: 14-day dual therapy with rabeprazole and amoxicillin (four times daily) achieved good efficacy, safety and compliance for the first-line eradication of Helicobacter pylori infection. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs was written by Patel, Harilal;Desai, Nirmal;Patel, Prakash;Modi, Nirav;Soni, Krunal;Rameshchandra Patel, Jitendrakumar;Navinbhai Mistry, Gaurav;Patel, Jitendrakumar D.;Chawla, Manish;Srinivas, Nuggehally R.. And the article was included in Drug Development and Industrial Pharmacy in 2019.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

To develop novel dual release prototype capsule formulations of rabeprazole and evaluation of pharmacokinetic properties relative to the reference product (Aciphex) in Beagle dogs. The dual release prototype formulations for rabeprazole were developed by preparing optimized mini-tablets core which was subsequently coated with barrier/enteric coating using standard excipients. Both novel prototype formulations were subjected for in vitro release and assay by HPLC-UV to assess long term stability. Single dose pharmacokinetic study used a single sequence three treatments crossover design. In Periods 1 and 2, four dogs received oral 20 mg dose of two prototype formulations. In Period 3, all dogs recieved a 20 mg oral dose of Aciphex reference product. There was a 1-wk washout time between two successive periods. A quant. anal. of rabeprazole/sulfide metabolite in plasma samples was performed using a validated LC-MS/MS assay and PK parameters were estimated by non-compartmental anal. The stability of the prototype formulations was confirmed over a period of 24 mo with an acceptable assay and dissolution data. One of the novel prototype formulations showed 70% oral bioavailability relative to the reference product. Despite a 30% reduced bioavailability, this showed 1 h delay in peak concentration, longer plasma residence time of rabeprazole (up to 12 h) and longer apparent elimination half-life. The use of a canine model has enabled the selection of a novel dual-release prototype formulation of rabeprazole for further clin. development. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Probing interfacial behaviors of Bronsted acidic ionic liquids improved isobutane alkylation with C4 olefin catalyzed by sulfuric acid was written by Sun, Weizhen;Zheng, Weizhong;Cao, Piao;Zhao, Ling. And the article was included in Chemical Engineering Journal (Amsterdam, Netherlands) in 2019.Related Products of 478935-29-4 The following contents are mentioned in the article:

The interfacial microenvironments between catalysts and C4 hydrocarbons for the isobutane alkylation is of vital importance to producing high-quality alkylate. In the present work, the interfacial properties between Bronsted acidic ionic liquids (BILs)/H₂SO₄ and C4 mixtures, as well as between the cationic and anionic surfactants/H₂SO₄ and C4 mixtures were investigated using mol. dynamic (MD) simulations, in which BILs share different alkyl chain length on cations with or without a sulfonic acid group. It indicated both BILs and surfactants can enhance the H₂SO₄/C4 reactants interfacial properties and facilitate C4 reactants dissolution, contributing to a better catalytic performance. The enhancement of the interfacial properties can be ascribed into the stronger d. enrichment and perpendicular behaviors of the longer alkyl chains at the interface. Compared to non-SFILs, sulfonic-acid-functionalized Bronsted acidic ionic liquids (SFILs) can facilitate a higher dissolution of isobutane in both bulk and interfacial regions, but result in a lower interfacial diffusion. In addition, the much stronger interfacial enrichment of surfactants without mixing with H₂SO₄ leads to a worse catalytic performance than BILs. However, the better mixing between BILs and H₂SO₄ leading to better catalytic performance suggests the important role of the BILs acting as phase transfer catalyst for the H₂SO₄-catalyzed alkylation. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Related Products of 478935-29-4).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Related Products of 478935-29-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors was written by Yamashita-Kashima, Yoriko;Yorozu, Keigo;Fujimura, Takaaki;Kawasaki, Natsumi;Kurasawa, Mitsue;Yoshiura, Shigeki;Harada, Naoki;Kondoh, Osamu;Yoshimura, Yasushi. And the article was included in International Journal of Hematology in 2022.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

The glycoengineered, humanized anti-CD20 antibody obinutuzumab is indicated for previously untreated or relapsed/refractory CD20-pos. follicular lymphoma (FL). However, the effectiveness of obinutuzumab retreatment in relapsed/refractory FL after prior obinutuzumab-containing therapy is unclear. To address this issue, we investigated the antitumor activity of obinutuzumab plus bendamustine in obinutuzumab-resistant tumors established from a human non-Hodgkin lymphoma xenograft model. Obinutuzumab-resistant tumors (SU-DHL-4-OR-18-8) were established from an SU-DHL-4 xenograft model by repeated administration of obinutuzumab. Antitumor activity was evaluated based on tumor volume after treatment with obinutuzumab on Day 1, 8, and 15 and/or bendamustine on Day 1 and 2. Intratumoral natural killer (NK) cells/macrophages were evaluated by immunohistochem. and flow cytometry. In SU-DHL-4-OR-18-8 xenografted tumors, intratumoral NK cells/macrophages after obinutuzumab treatment were significantly decreased compared with parent tumors on Day 4. The endoplasmic reticulum stress sensor phospho-IRE1 was also decreased. In SU-DHL-4-OR-18-8 tumors, bendamustine treatment increased phospho-IRE1 on Day 4 and intratumor NK cells/macrophages on Day 10. Obinutuzumab combined with bendamustine significantly increased antitumor activity compared with each single agent on Day 29, with an increase in chemoattractant CCL6 expression on Day 10. Coadministration of bendamustine in obinutuzumab retreatment may be effective against obinutuzumab-resistant tumors. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis was written by Avivi, Irit;Perry, Chava;Segman, Yafit;Amit, Odelia;Bar-On, Yaeli;Katz, Ofrat Beyer;Gold, Ronit;Ribakovsky, Elena;Avigdor, Abraham;Vainstein, Vladimir;Goldschmidt, Neta;Ringelstein-Harlev, Shimrit;Horowitz, Netanel A.;Gutwein, Odit;Gurion, Ronit;Itchaki, Gilad;Abadi, Uri;Nemets, Anatoly;Sofer, Orit;Vezker, Miri;Tadmor, Tamar;Dally, Najib;Filanovsky, Kalman;Leiba, Merav;Sarid, Nadav;Benyamini, Noam;Luttwak, Efrat;Herishanu, Yair;Ram, Ron. And the article was included in Annals of Hematology in 2022.Product Details of 16506-27-7 The following contents are mentioned in the article:

Polatuzumab (Pola)-based regimens and chimeric antigen receptor T (CAR T) cells provide superior outcome compared to conventional chemoimmunotherapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). Choosing between these strategies remains controversial. The efficacy of CAR T vs. Pola-rituximab(R) /Pola-bendamustine(B)-R in R/R DLBCL patients after failing ≥2 lines of treatment was compared in a retrospective, ‘real-world’ study. Propensity score matching, for age, lymphoma category (de-novo/transformed), number of prior lines, Eastern Cooperative Oncol. Group performance status and lactate dehydrogenase level, was applied to control for differences in patients’ characteristics. Response rate, progression-free survival (PFS) and overall survival (OS) were analyzed. A total of 82 patients, treated with CAR T (n = 41) or Pola-based regimens (n = 41), were included. No treatment-related deaths occurred with CAR T vs. 3 (7.3%) with Pola. The overall and complete response rates were 83% and 58% with CAR T vs. 66% and 44% with Pola-based-regimens (p = 0.077 and p = 0.18, resp.). At a median follow-up of 9 mo (range 1-19.2) and 16 mo (range 0.7-25.3) for the CAR T and Pola arm resp., the median PFS has not been reached for CAR T vs. 5.6 mo for Pola (95% CI 3.6-7.6, p = 0.014). Median OS has not been reached for CAR T vs. 10.8 mo (95% CI 2.2-19.4) for Pola (p = 0.026). To conclude, in a real-world setting, treatment with CAR T achieved superior PFS and OS compared to Pola-based regimens in patients with R/R DLBCL. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Product Details of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Product Details of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication was written by Kikuchi, Sota;Nobeyama, Yoshimasa;Saeki, Hidehisa;Asahina, Akihiko. And the article was included in Journal of Dermatology in 2020.Name: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Cutaneous adverse drug reactions (cADR) should be appropriately managed in drug administration. LANSAP, Rabecure and VONOSAP are currently used for Helicobacter pylori eradication therapy. Here, we examined the characteristics of cADR caused by these drugs using data from the Pharmaceuticals and Medical Devices Agency (PMDA). Periods subject to analyses were set according to the year of release of these drugs: (i) from 2008 to 2017 for LANSAP; (ii) from 2014 to 2017 for Rabecure; and (iii) 2017 for VONOSAP. Among all cADR reported to the PMDA, those attributed to LANSAP, Rabecure and VONOSAP accounted for 2.3%, 1.0% and 3.6% of cases, resp. cADR occurred in patients aged in their 20s or older, with the oldest patients aged in their 60s. Numbers of male and female patients were 28 and 70 for LANSAP, eight and 14 for Rabecure and three and 16 for VONOSAP, resp. Statistical analyses revealed significant sex differences for LANSAP (P = 0.022) and VONOSAP (P = 0.012), but not for Rabecure (P = 0.729). LANSAP, Rabecure or VONOSAP caused erythema multiforme in the largest population of patients and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in three patients. Ratios of SJS/TEN were 0.0-5.3% for LANSAP, Rabecure or VONOSAP, but 11.5-44.8% for the corresponding single constituent drugs other than vonoprazan. In conclusion, female sex appears to represent a risk factor for cADR attributed to H. pylori eradication therapy using LANSAP or VONOSAP, although H. pylori eradication therapy without these drugs rarely causes severe cADR. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Name: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Name: Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO/GETH Spanish groups was written by Bastos-Oreiro, Mariana;Gutierrez, Antonio;Reguera, Juan Luis;Iacoboni, Gloria;Lopez-Corral, Lucia;Terol, Mara Jose;Ortiz-Maldonado, Valentin;Sanz, Jaime;Guerra-Dominguez, Luisa;Bailen, Rebeca;Mussetti, Alberto;Abrisqueta, Pau;Hernani, Rafael;Luzardo, Hugo;Sancho, Juan-Manuel;Delgado-Serrano, Javier;Salar, Antonio;Grande, Carlos;Bento, Leyre;de Villambrosa, Sonia Gonzalez;Garcia-Belmonte, Daniel;Sureda, Anna;Perez-Martinez, Antonio;Barba, Pere;Kwon, Mi;Garcia-Sancho, Alejandro Martin. And the article was included in Frontiers in Immunology in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with com. CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 mo, p ≤ 0.001) and overall survival (OS) (median of 15 vs. 8 mo, p < 0.001), independently of other prognostic factors (HR: 0.59 (95% CI: 0.44-0.80); p < 0.001 for PFS, and 0.45 (95% CI: 0.31-0.64) for OS). Within the CAR-T cohort, axi-cel showed longer PFS (median of 7.3 vs. 2.8 mo, resp., p = 0.027) and OS (58% vs. 42% at 12 mo, resp., p = 0.048) than tisa-cel. These differences were maintained in the multivariable anal. On the other hand, axi-cel was independently associated with a higher risk of severe cytokine release syndrome and neurotoxicity. Our results suggest that the efficacy of CAR-T cell therapy is superior to pSOC in the real-world setting. Furthermore, axi-cel could be superior in efficacy to tisa-cel, although more toxic, in this group of refractory patients according to SCHOLAR-1 criteria. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Performance and Mechanism of Alkylimidazolium Ionic Liquids as Corrosion Inhibitors for Copper in Sulfuric Acid Solution was written by Tian, Guocai;Yuan, Kaitao. And the article was included in Molecules in 2021.SDS of cas: 478935-29-4 The following contents are mentioned in the article:

The addition of corrosion inhibitors is an economic and environmental protection method to prevent the corrosion of copper. The adsorption, performance, and mechanism of three 1-alkyl-3-methylimidazolium hydrogen sulfate ([BMIM]HSO4, [HMIM]HSO4, and [OMIM]HSO4) ionic liquids (ILs) on the copper surface in 0.5 M H₂SO₄ solutions were studied by quantum chem. calculation, quant. structure-activity relationship (QSAR), and mol. dynamics simulation. It is found that the main reactive site is located on the imidazolium ring (especially the C2, N4, and N7 groups). When the alkyl chain of the imidazolium ring is increasing, the mol. reactivity of the ILs and the interaction between the ILs inhibitor and copper surface are enhanced. The imidazole ring of the ILs tends to be adsorbed on Cu (111) surface in parallel through phys. adsorption. The order of adsorption energy is [Bmim]HSO4 < [Hmim]HSO4 < [OMIM]HSO4, which is in agreement with the exptl. order of corrosion efficiency. On the imidazole ring, the interaction between the copper surface and the C atom is greater than that between the copper surface and the N atom. It is found that ILs addition can hinder the diffusion of corrosion particles, reduce the number d. of corrosion particles and slow down the corrosion rate. The order of inhibition ability of three ILs is [Bmim]HSO4 < [Hmim]HSO4 < [OMIM]HSO4,which agree well with exptl. results. A reliable QSAR correlation between the inhibition corrosion efficiency and mol. reactivity parameters of the ILs was established. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4SDS of cas: 478935-29-4).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.SDS of cas: 478935-29-4

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem